INM News and Press, InMed Pharmaceuticals Inc. From 06/14/22

VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-re...

THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and even appetite, weight/BMI, according to InMed Pharmaceuticals Inc.’s (NASDAQ: INM). In addition, according to LAweekly.com, THCV benefits are reported to be pretty incredible, includi...

InMed Pharmaceuticals (NASDAQ:INM) (OTCQX:IMLFF) said it launched B2B (business-to-business) sales of rare cannabinoid delta 9-dominant tetrahydrocannabivarin (d9-THCV) in the health and wellness sector via its subsidiary BayMedica. "In anticipation of this launch, we have expanded internal s...

Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoid Bolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBT THCV has been researched for a variety of potential benefits VANCOUVER, British Columbia, J...

InMed Pharmaceuticals (NASDAQ: INM) , a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were pr...

VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed ” or the “ Company ”) ( Nasdaq: INM ), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced ...

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sa...

InMed Pharmaceuticals (NASDAQ:INM) -4% has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4.08M common shares at a purchase price of $0.858 per share (or pre-funded warrant in lieu thereof) in a regist...

VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“ InMed ” or the “ Company ”) ( Nasdaq: INM ), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced ...

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancem...